Apollomics Inc.
Apollomics Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS on March 1, 2027. There are 4 upcoming events on record.
| Date | Event | Type | Phase |
|---|---|---|---|
| March 1, 2027 | A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS | Trial Milestone | Phase 1 |
| May 18, 2027 | A Study of APL-10456-Vaccine | Trial Milestone | EARLY_Phase 1 |
| August 30, 2027 | A Trial of "APL-9796'' in Adults With Pulmonary Hypertension | Trial Milestone | Phase 2 |
| October 31, 2027 | A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | Trial Milestone | Phase 2 |
Track APLM alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open APLM in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.